Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Patient-reported outcomes in a phase II study of alectinib.

Ohe Y.

ESMO Open. 2018 Jul 15;3(5):e000412. doi: 10.1136/esmoopen-2018-000412. eCollection 2018. No abstract available.

2.

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.

Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT.

ESMO Open. 2018 Jul 12;3(5):e000364. doi: 10.1136/esmoopen-2018-000364. eCollection 2018.

3.

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.

Tamura T, Kiura K, Seto T, Nakagawa K, Maemondo M, Inoue A, Hida T, Yoshioka H, Harada M, Ohe Y, Nogami N, Murakami H, Kuriki H, Shimada T, Tanaka T, Takeuchi K, Nishio M.

J Clin Oncol. 2017 May 10;35(14):1515-1521. doi: 10.1200/JCO.2016.70.5749. Epub 2017 Mar 15.

4.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.

Lancet Oncol. 2014 Sep;15(10):1119-28. doi: 10.1016/S1470-2045(14)70362-6. Epub 2014 Aug 18.

PMID:
25153538
5.

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA.

DiBonaventura MD, Wong W, Shah-Manek B, Schulz M.

Onco Targets Ther. 2017 Dec 22;11:75-82. doi: 10.2147/OTT.S144960. eCollection 2018.

6.

Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol.

Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S.

J Med Invest. 2017;64(3.4):317-320. doi: 10.2152/jmi.64.317.

7.

Alectinib for treatment of ALK-positive non-small-cell lung cancer.

Avrillon V, PĂ©rol M.

Future Oncol. 2017 Feb;13(4):321-335. doi: 10.2217/fon-2016-0386. Epub 2016 Oct 26. Review.

PMID:
27780368
8.

Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.

McKeage K.

Drugs. 2015 Jan;75(1):75-82. doi: 10.1007/s40265-014-0329-y. Review. Erratum in: Drugs. 2015 Feb;75(2):241.

PMID:
25428710
9.

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.

Yoshimura Y, Kurasawa M, Yorozu K, Puig O, Bordogna W, Harada N.

Cancer Chemother Pharmacol. 2016 Mar;77(3):623-8. doi: 10.1007/s00280-016-2977-y. Epub 2016 Feb 5.

PMID:
26849637
10.

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.

Lung Cancer. 2015 May;88(2):231-4. doi: 10.1016/j.lungcan.2015.02.005. Epub 2015 Feb 12.

PMID:
25736571
11.

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

Lin JJ, Kennedy E, Sequist LV, Brastianos PK, Goodwin KE, Stevens S, Wanat AC, Stober LL, Digumarthy SR, Engelman JA, Shaw AT, Gainor JF.

J Thorac Oncol. 2016 Nov;11(11):2027-2032. doi: 10.1016/j.jtho.2016.08.126. Epub 2016 Aug 17.

12.

In vitro and in vivo anti-tumor activity of alectinib in tumor cells with NCOA4-RET.

Arai S, Kita K, Tanimoto A, Takeuchi S, Fukuda K, Sato H, Yano S.

Oncotarget. 2017 May 16;8(43):73766-73773. doi: 10.18632/oncotarget.17900. eCollection 2017 Sep 26.

13.

An UPLC-MS/MS method for the quantitation of alectinib in rat plasma.

Huang XX, Li YX, Li XY, Hu XX, Tang PF, Hu GX.

J Pharm Biomed Anal. 2017 Jan 5;132:227-231. doi: 10.1016/j.jpba.2016.10.010. Epub 2016 Oct 14.

PMID:
27768922
14.

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung.

Imanishi N, Yoneda K, Taira A, Ichiki Y, Sato N, Hisaoka M, Tanaka F.

Surg Case Rep. 2018 Mar 9;4(1):19. doi: 10.1186/s40792-018-0430-7.

15.

Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.

Morcos PN, Cleary Y, Guerini E, Dall G, Bogman K, De Petris L, Viteri S, Bordogna W, Yu L, Martin-Facklam M, Phipps A.

Clin Pharmacol Drug Dev. 2017 May;6(3):280-291. doi: 10.1002/cpdd.298. Epub 2016 Sep 28.

PMID:
27545757
16.

The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.

Carlson JJ, Canestaro W, Ravelo A, Wong W.

J Med Econ. 2017 Jul;20(7):671-677. doi: 10.1080/13696998.2017.1302453. Epub 2017 Mar 23.

PMID:
28332433
17.

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.

Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, Iafrate AJ, Takeuchi K, Taiji M, Okuno Y, Fujita N, Engelman JA, Shaw AT.

Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.

18.

Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.

Nitawaki T, Sakata Y, Kawamura K, Ichikado K.

BMC Pulm Med. 2017 Dec 6;17(1):173. doi: 10.1186/s12890-017-0519-y.

19.

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.

Santarpia M, Altavilla G, Rosell R.

Expert Rev Respir Med. 2015 Jun;9(3):255-68. doi: 10.1586/17476348.2015.1009040. Epub 2015 Feb 5.

PMID:
25652176
20.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators.

Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. Erratum in: Lancet Oncol. 2017 Mar;18(3):e134.

Supplemental Content

Support Center